Terns Pharmaceuticals Inc TERN

$52.95 +0.02 (0.04%)

Valuation

Market cap
6,116,838,000
Revenue TTM
$0
Net income TTM
$-96,210,000
PE ratio
0.00
Forward PE
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
6,347,000
Avg volume
6,722,514
Day's range
$52.94 – $52.98
Shares out
115,521,000
Stochastic %K
85%
Beta
-0.37
Analysts
Hold
Price target
$53.00

Price

Company profile

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in Phase 1/2 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta...

Show more

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in Phase 1/2 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced metabolic stability and liver distribution that is in Phase IIa clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis (MASH); and TERN-801 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California. As of May 4, 2026, Terns Pharmaceuticals, Inc. operates as a subsidiary of Merck Sharp & Dohme LLC.

Industry
Biotechnology
Sector
Healthcare
Phone
650 525 5535
Website
https://www.ternspharma.com
Address
1065 East Hillsdale Boulevard, Suite 100, Foster City, United States

Latest news

Stocktwits

gnarled15 Oct 20, 7:58 PM
$SLS giving off $TERN vibes.
1 replies
55X_ROI_Q1_2026 Oct 19, 5:28 AM
$SLS $RVMD The good news for all of us Loading in here, is Gps is 99.999% for Sure Golden, and if you are not sure, as a hedge, the secondary asset sls009 is already worth 2x - 3x the current rigged/manipulated as f $2.03B mcap - based on the Prior P2 AML-MR Data $5B $FTSV $TERN $7B Comps, + the ongoing Randomized Pivotal Front Line SLS009 trial - and then add in the fact 009 is 6x More Effective for PDAC than daraxonrasib - a $40B Platform Drug.... https://www.globenewswire.com/news-release/2026/09/02/3355136/0/en/sellas-life-sciences-to-present-preclinical-data-on-sls009-in-pancreatic-ductal-adenocarcinoma-at-the-2026-aacr-conference-on-pancreatic-cancer.html
0 replies
55X_ROI_Q1_2026 Oct 19, 4:07 AM
$SLS foe those who don’t know- Completed SLS009 Phase 2 AML-MR Data Published at ASH Last December - is already worth 2x the current $2.03B Manipulated mcap. • 009 Now in Phase 2 AML-MR Expansion Trial at the Request of FDA: • 80 patients • Dual Arm • Randomized and • PIVOTAL* • with FDA Greenlight Data incoming this quarter - in Q4 Previous P2 SLS009 Data Increased Survival 4x / 50% ORR in END STAGE AML-MR - 50% ORR in Dying AML Patients! -- we Absolutely Know 009 is going to BE SUCCESSFUL in Newly Diagnosed - Front Line and Ven Aza 1 Line Failed Patients. - AML-MR is the most Dire of AML Prognoses, often results from other cancer treatment, chemo radiation. • list FDA approved drugs based on Ph1/2 data like the trial 009 is now in. "The FDA has asked tambiciclib's developer to start a trial investigating the combination in front-line acute myeloid leukemia." https://www.cancernetwork.com/view/tambiciclib-plus-ven-aza-met-all-primary-end-points-in-r-r-aml-trial ​$FTSV $TERN
0 replies
55X_ROI_Q1_2026 Oct 13, 6:36 AM
$SLS $MRNA $TERN Expect the SLS Share Price to Climb from here on out to the Imminent 80th Event PR and the GPS Phase 3 Results - a FDA Green Light to treat 50,000 AML Remission Patients Each Year. Gps Immunotherapy is getting Fda GREENLIGHT to Treat 100,000 AML patients CURRENTLY in Remission - right out of the GATE. The Co Estimated a Minimum of $300K Revenue Per Patient Year 1. Indefinite Multi Year Dosing Regime Compounds the Rev for 5+ Years. - $28B Total Addressable Market - Right out of the GATE Plus 12,500 AML CR2/3 Patients who are Eligible Each Year ... Just this CR2/3 Market is worth $125 Per Share.
0 replies
55X_ROI_Q1_2026 Oct 7, 3:54 PM
$SLS --- You could have bought this at $11.40 .... I will be posting this for all the flipping Idiots ... when this is $120 and climbing. For years, when the multiple doctors treating actual GPS P3 Patients were stating BAT is Toxic, its effective in achieving remission for more patients, but the Survival is Not Durable --- VIALE-M was still Out There - BAT Aza+VEN in a P3 for CR1 Transplant Ineligible... Now VIALE-M is DEAD VIALE-T DEAD VERONA DEAD OptiAML DEAD ParaDIGM DEAD Control Patients in the SLS P3 on BAT - are DEAD ... Sad to Say ... but true. https://www.reddit.com/r/sellasLifescience/comments/1wzb5d4/bat_for_the_sls_control_arm_patients_has_failed_5/ $MRNA $FTSV $TERN
0 replies
SellasgpsCurativeBAT11 Oct 6, 7:47 PM
$SLS Never seen or heard of a QP for 3 months that’s data related. I have been involved in 2 stocks with extended QP $CDTX $TERN both got BO. ✌️🙏❤️‍🩹
0 replies
SellasgpsCurativeBAT11 Sep 30, 5:25 PM
$CDTX $MRK $SLS $TERN Big Pharmaceuticals due to $380 Billion patent cliff averaging 2 deals a week so far this year. Sellas Next up! ✌️🙏❤️‍🩹
0 replies
SellasgpsCurativeBAT11 Sep 30, 12:16 AM
$SLS $MRK $CDTX $TERN The SciBrunch deal is Merck's latest move to bolster its pipeline as it braces for the loss of patent protection for its blockbuster cancer drug Keytruda in 2028. Merck in May completed its nearly $6 billion acquisition of cancer biotech Terns Pharmaceuticals and its promising leukemia treatment, and the company in January wrapped up its $9.2 billion purchase of Cidara Therapeutics, a biotech making a new flu prevention drug. Biotechnology sector M&A is extremely hot right now due to $380 Million in patent cliffs. Big pharmaceuticals are buying up small to mid stage up front for massive premiums or Partnership deals. $SLS will be Acquired for $30- $40 Billion making it the biggest biotech deal of 2026. Mark this post ! ✌️🙏❤️‍🩹
0 replies